Exelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel Sells 50,000 Shares of Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel sold 50,000 shares of Exelixis stock in a transaction on Friday, November 1st. The shares were sold at an average price of $34.13, for a total value of $1,706,500.00. Following the completion of the transaction, the executive vice president now owns 530,325 shares of the company’s stock, valued at approximately $18,099,992.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Jeffrey Hessekiel also recently made the following trade(s):

• On Monday, October 28th, Jeffrey Hessekiel sold 25,000 shares of Exelixis stock. The shares were sold at an average price of $28.39, for a total value of $709,750.00.
• On Monday, September 23rd, Jeffrey Hessekiel sold 25,000 shares of Exelixis stock. The shares were sold at an average price of $26.38, for a total value of $659,500.00.
• On Monday, August 26th, Jeffrey Hessekiel sold 20,000 shares of Exelixis stock. The shares were sold at an average price of $25.79, for a total value of $515,800.00.

Exelixis Stock Up 1.4 %

Shares of EXEL stock opened at $34.77 on Wednesday. The stock has a market capitalization of $9.93 billion, a PE ratio of 22.08, a price-to-earnings-growth ratio of 0.92 and a beta of 0.51. Exelixis, Inc. has a 52-week low of $19.20 and a 52-week high of $35.15. The stock’s 50-day moving average price is $27.30 and its 200 day moving average price is $24.39.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.04. The firm had revenue of $539.50 million for the quarter, compared to analysts’ expectations of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.10 EPS. Analysts expect that Exelixis, Inc. will post 1.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Exelixis

Several institutional investors have recently added to or reduced their stakes in EXEL. First Trust Direct Indexing L.P. purchased a new stake in Exelixis in the 1st quarter valued at approximately $250,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Exelixis by 3.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 35,771 shares of the biotechnology company’s stock valued at $778,000 after purchasing an additional 1,301 shares in the last quarter. Janney Montgomery Scott LLC boosted its holdings in Exelixis by 6.1% in the 1st quarter. Janney Montgomery Scott LLC now owns 60,746 shares of the biotechnology company’s stock valued at $1,442,000 after purchasing an additional 3,510 shares in the last quarter. Nordea Investment Management AB boosted its holdings in Exelixis by 17.3% in the 1st quarter. Nordea Investment Management AB now owns 202,292 shares of the biotechnology company’s stock valued at $4,835,000 after purchasing an additional 29,784 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Exelixis in the 1st quarter valued at approximately $1,281,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. UBS Group assumed coverage on Exelixis in a report on Thursday, September 19th. They issued a “neutral” rating and a $30.00 target price for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $34.00 price target on shares of Exelixis in a report on Wednesday, October 30th. StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 13th. Morgan Stanley lifted their price target on Exelixis from $26.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, October 11th. Finally, TD Cowen lifted their price target on Exelixis from $27.00 to $34.00 and gave the stock a “buy” rating in a report on Monday, October 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $31.44.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.